Neurotech, a company dedicated to delivering biological therapeutics, has announced positive results from two Phase 3 studies of NT-501, a cell therapy implant to treat Type 2 macular telangiectasia.

In Type 2 macular telangiectasia, the blood vessels dilate and leak, causing swelling of the macula.

In one phase 3 trial, Neurotech associated NT-501 to a 56.4% rate of change in ellipsoid zone area loss from baseline through 24 months. The rate of change in the second study was 29.2%.

Click here to read the entire article.